Press Releases

WASHINGTON, DC—Following today’s announcement that Eli Lilly’s drug that would slow memory loss in people with mild cases of Alzheimer’s disease failed Phase III clinical trials, UsAgainstAlzheimer’s emphasizes that while this news is a setback for the millions of people around the world with dementia, the pipeline could see more successful results in the near future.

WASHINGTON, DC, November 15, 2016 – A multigenerational movement to defeat Alzheimer’s disease, buoyed by the partnership of UsAgainstAlzheimer’s  and a host of national, state and local Alzheimer’s-serving organizations, was catalyzed during this fall’s National Alzheimer’s Summit in Washington, DC, proving to be a decisive moment in a fight against a disease that is the nation’s third-leading cause of death.  

UsAgainstAlzheimer’s Urges Executive and Congressional Action in the First 100 Days and Beyond

WASHINGTON, DC, November 10, 2016—As the United States turns its attention to forging constructive transitions in the executive and legislative branches, UsAgainstAlzheimer’s (UsA2) calls upon the newly elected Administration and Congress to shepherd in an era that finally addresses the serious national priority that is Alzheimer’s and related dementias, and takes immediate action to increase Alzheimer’s research funding and to support patients and caregivers.

WASHINGTON, DC—The Centers for Medicare & Medicaid Services (CMS) announced this week that people with Alzheimer’s or other dementias will now be able to access critical assessment and care-planning services and have it paid for as part of their Medicare benefit. 

WASHINGTON, DC—Former U.S. Surgeon General Dr. David Satcher was officially announced as a new member of the UsAgainstAlzheimer’s (UsA2) Board of Directors, where he will add his voice and influence to a movement calling for urgency and action to defeat a disease that is the third leading cause of death In the United States.


^ Back to Top